Navigation Links
Leukemia Drug Proves Safe and Effective Over the Long Term
Date:11/7/2007

WASHINGTON, Nov. 7, /PRNewswire-USNewswire/ -- The drug imatinib mesylate, more commonly known as Gleevec(R), proves safe and effective over the long term in patients with an advanced form of chronic myeloid leukemia (CML), according to a study prepublished online in Blood, the official journal of the American Society of Hematology.

A team of researchers from the U.S. and Europe, including the drug's creator, Brian Druker, MD, followed 454 patients with chronic-phase CML taking imatinib for more than six years. Prior to enrollment, all study participants had experienced either treatment failure or intolerance with interferon alpha, which was the standard of care for CML at the time the study was initiated.

"The long-term follow-up results of imatinib in CML post interferon failure reassure us of the high efficacy of the drug and its safety," stated Hagop Kantarjian, MD, the lead author on the study and Chairman and Professor of the Leukemia Department at the University of Texas M.D. Anderson Cancer Center. "With a six-year follow-up, the estimated six-year survival rate is 76 percent. In historical data, after interferon failure the average survival was about three to four years."

Imatinib dosage began at 400 milligrams per day and was escalated to 600 mg/d or 800 mg/d in patients who did not achieve positive treatment responses within set time periods or whose disease relapsed.

The best possible treatment outcome -- a complete cytogenetic response, which is the elimination of the genetic abnormality associated with the disease -- occurred in 57 percent of the study participants and was achieved in a median time of eight months. Overall survival rates and avoidance of disease progression were strongly correlated with cytogenetic response by 12 months; those with a minimal or no cytogenetic response within the first year faired poorly.

The incidence of serious side effects was low and, although 15 cases of heart dysfunction w
'/>"/>

SOURCE American Society of Hematology
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
2. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
3. St. Jude Discovers Factors That Accelerate Resistance to Gleevec(TM) Targeted Therapy in Lymphoblastic Leukemia
4. September is Leukemia, Lymphoma and Myeloma Awareness Month
5. The Leukemia & Lymphoma Society is Encouraged by Promising News for Myeloma Patients
6. The Leukemia & Lymphoma Society and Cleveland Clinic Taussig Cancer Institute Announce Groundbreaking Partnership to Accelerate Drug Approvals
7. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
8. Experimental Drug Ketasyn(TM) Improves Memory in Age-Associated Memory Impairment Study
9. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
10. First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
11. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... GROVE, Minn. , May 22, 2013 ... announced the successful completion of its global ... topiramate), an internally developed program for the ... company,s proprietary formulation technology.  USL255 is specifically ... reduce fluctuations in topiramate blood levels observed ...
(Date:5/22/2013)... , May 22, 2013  Generex Biotechnology Corporation ... demonstrating the superiority of the AE37 breast cancer vaccine ... ( www.antigenexpress.com ). The presentations will be made at ... Oncology (ASCO) to be held in Chicago ... The presentation entitled " Booster inoculations of ...
(Date:5/22/2013)...  Grifols, ein globales Unternehmen der Gesundheitsbranche ... , Spanien, präsentierte die Ergebnisse einer Studie, ... PROLASTIN©-C (Alpha1-Proteinasehemmer [human]) den Spiegel des Alpha1-Proteins ... Niveau anhebt, das innerhalb des für gesunde ... eine lebensbedrohliche, genetische Erkrankung, bei der der ...
Breaking Medicine Technology:Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 2Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 3Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 4Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 2Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 3Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 4Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 2Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 3Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 4
(Date:5/22/2013)... that hospitals may be reaping enormous income for ... bloodstream infections contracted in their intensive care units. ... in the American Journal of Medical Quality ... who develops an avoidable central line-associated bloodstream infection ... for than a similar infection-free patient. Moreover, hospitals ...
(Date:5/22/2013)... 22, 2013 Recent tragedies including ... the school shooting in Newtown, Connecticut all resulted ... , Emergency medical practitioners train to respond ... Emergency Medical Services for Children (EMSC) Program specifically ... for the youngest patients. It is estimated 30 ...
(Date:5/22/2013)... 22, 2013 Space Girl Organics ... sponsor for this weekend's I Talk to Strangers Miracle ... am at Cocoa Riverside Park in Cocoa, FL. The event ... Talk to Strangers social movement. , As a sponsor, Space ... to participate in the event. Additionally, they are providing bananas ...
(Date:5/22/2013)... Pamela Isom, President and CEO of ICE ... 2013 Women of Influence Award in recognition for her ... reception took place on Thursday, May 2 at The ... particularly humbling for the 5,000 people ICE Safety Solutions ... to recognize the four to nine lives saved per ...
(Date:5/22/2013)... 2013 Homeopathic Vibes is implementing new store ... to the store during normal hours. On Wednesdays, they will ... to accommodate some of our patients who work shifts that ... or on Saturdays,” says owner and homeopathic consultant, Harminder Singh. ... 6 p.m. Monday through Friday; weekends are by appointment only. ...
Breaking Medicine News(10 mins):Health News:Hospitals profit when patients develop bloodstream infections 2Health News:Hospitals profit when patients develop bloodstream infections 3Health News:Hospitals profit when patients develop bloodstream infections 4Health News:When Tragedies Impact Children – Kentucky Emergency Medical Services for Children (KYEMSC) Offers Specialized Training for Pediatric Emergency Care 2Health News:Space Girl Organics to Sponsor May 25 Miracle Run/Walk 2Health News:Pamela Isom, President and CEO of ICE Safety Solutions Inc. Receives 2013 Women of Influence Recognition and Award 2Health News:Homeopathic Vibes Now Open Late on Wednesdays 2
... YORK, NY, Sept. 10 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - ... acquires, and develops novel drug targets that disrupt the ... a patent for a potential blockbuster drug target that ... a tailor-made lipid which induces cell death in breast ...
... Immediately after President Obama,s speech to a Joint Session of ... nation,s top political, legislative and communications strategists -- representing a ... and public relations. , , The ... very happy with the speech, but most reactions were short ...
... ... rights to a suite of intellectual property owned by Spherofix AB. , ... Charlotte, NC (PRWEB) September 10, ... acquired exclusive rights to a suite of intellectual property owned by Spherofix AB., , ...
... Netherlands, September 10 The Danish Council,for Strategic Research ... Thursday, September 10. The purpose of their visit is ... and the concrete results,that are being booked by this ... cited TI Pharma as a prime example of public-private,collaboration ...
... Sept. 9 Family Research Council President Tony Perkins made ... a joint session of Congress. , , ... , Tomorrow night in a live webcast at ... address. Perkins will be joined by Senator Jim DeMint (R-SC), ...
... , WASHINGTON, Sept. 9 America,s ... Ignagni, President and CEO: , , "We agree ... plans last year did something industries rarely do: stepped up and ... American people. We proposed health insurance reform to guarantee coverage ...
Cached Medicine News:Health News:GENova files patent for new breast cancer treatment 2Health News:Clarus Research Group Survey: Top Political Strategists React to Obama's Health Care Speech, Rate Effectiveness 2Health News:Clarus Research Group Survey: Top Political Strategists React to Obama's Health Care Speech, Rate Effectiveness 3Health News:Kapstone Medical Acquires Exclusive License to New Orthopedic Technology 2Health News:Dutch Top Institute Pharma Attracts International Interest 2Health News:President Obama's Campaign Style Speech Points to a Health Care Plan on Life Support 2
... range of diagnosis by using the Convex Scanning ... clear image of blood flow by using the ... accessory elevator has been incorporated and the balloon ... for more advanced and accurate techniques. The FG-36UX ...
... ACL 10000 allows you to maximize your ... staff are limited. This fully automated system ... analysis and advanced robotics, to ensure testing ... the ACL 10000 is backed by our ...
The SYNCHRON CX7-S workstation offers a broad menu, advanced data management and more. Targeted to the mid-volume lab, the CX7-S is easy to use, easy to maintain and easy to acquire....
... CX5 Delta takes the automation and ... and adds the benefit of electrolyte ... chemistry system for the low- to ... capabilities and continuous sample loading. The ...
Medicine Products: